Luminescent Iridium Complex-Peptide Hybrids (IPHs) for Therapeutics of Cancer: Design and Synthesis of IPHs for Detection of Cancer Cells and Induction of Their Necrosis-Type Cell Death

Bioinorganic Chemistry and Applications
Abdullah-Al MasumShin Aoki

Abstract

Death receptors (DR4 and DR5) offer attractive targets for cancer treatment because cancer cell death can be induced by apoptotic signal upon binding of death ligands such as tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) with death receptors. Cyclometalated iridium(III) complexes such as fac-Ir(tpy)3 (tpy = 2-(4-tolyl)pyridine) possess a C3-symmetric structure like TRAIL and exhibit excellent luminescence properties. Therefore, cyclometalated Ir complexes functionalized with DR-binding peptide motifs would be potent TRAIL mimics to detect cancer cells and induce their cell death. In this study, we report on the design and synthesis of C3-symmetric and luminescent Ir complex-peptide hybrids (IPHs), which possess cyclic peptide that had been reported to bind DR5. The results of 27 MHz quartz-crystal microbalance (QCM) measurements of DR5 with IPHs and costaining experiments of IPHs and anti-DR5 antibody, suggest that IPHs bind with DR5 and undergo internalization into cytoplasm, possibly via endocytosis. It was also found that IPHs induce slow cell death of these cancer cells in a parallel manner to the DR5 expression level. These results indicate that IPHs may offer a promising tool as artificial luminescent mi...Continue Reading

References

Jun 1, 1992·Trends in Pharmacological Sciences·W A Catterall, J Striessnig
Nov 1, 1984·The Journal of Physiology·W Van Driessche
Sep 1, 1984·Circulation Research·H J MotulskyP A Insel
Apr 4, 1997·Science·G PanV M Dixit
Jan 1, 1997·Annual Review of Pharmacology and Toxicology·G H HockermanW A Catterall
Oct 6, 1997·The EMBO Journal·H WalczakC T Rauch
Oct 7, 1997·The Journal of Experimental Medicine·M A Degli-EspostiC A Smith
Aug 28, 1998·Science·A Ashkenazi, V M Dixit
Jul 20, 1999·The Journal of Clinical Investigation·A AshkenaziR H Schwall
Jun 12, 2003·Journal of the American Chemical Society·Arnold B TamayoMark E Thompson
Aug 5, 2003·Inorganic Chemistry·Maria C DeRosaChristopher E B Evans
Jul 15, 2004·Current Opinion in Pharmacology·Sean K Kelley, Avi Ashkenazi
May 10, 2005·Bioorganic & Medicinal Chemistry Letters·Kosuke DodoMikiko Sodeoka
Aug 26, 2006·Chemistry : a European Journal·Michael S Lowry, Stefan Bernhard
Feb 6, 2007·Biochemical Pharmacology·David J Triggle
Aug 28, 2007·Analytical Chemistry·Sergey M Borisov, Ingo Klimant
Sep 8, 2007·Biochemical and Biophysical Research Communications·Chiaki KagaHiroyuki Honda
Apr 15, 2008·Nature Chemical Biology·Alexei DegterevJunying Yuan
Jul 22, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Avi AshkenaziS Gail Eckhardt
Apr 30, 2009·Advances in Experimental Medicine and Biology·Yvonne M AngellChristopher P Holmes
Jan 28, 2010·Cancer Research·Valeria PavetHinrich Gronemeyer
Jan 30, 2010·Chemical Society Reviews·Yun Chi, Pi-Tai Chou
Mar 4, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jeffrey WiezorekJonathan Graves
Dec 7, 2010·Biomacromolecules·Victor Z SunDaniel T Kamei
Jan 22, 2011·Chemical Society Reviews·Qiang ZhaoFuyou Li

❮ Previous
Next ❯

Methods Mentioned

BETA
quartz-crystal microbalance
FCS
Assay
FACS
flow cytometry

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.